NCT03370770View on ClinicalTrials.gov

Afatinib Osimertinib Sequencing NIS

CompletedOBSERVATIONAL
Enrollment

204

Participants

Timeline

Start Date

December 28, 2017

Primary Completion Date

November 28, 2019

Study Completion Date

November 28, 2019

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Afatinib

GILOTRIF, GIOTRIF, XOVOLTIB

DRUG

Osimertinib

on T790M resistance mutation was developed

Trial Locations (1)

1140

Otto-Wagner Hospital, Vienna

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY